Indien oncgnostics GmbH

From the 9 to the 16 In February, our managing director Dr Martina Schmitz travelled to India as a participant of the delegation trip ‘Thuringia goes India’. There she got an impression of the Indian market and made first contacts. The trip took place under the direction of Wolfgang Tiefensee, Thuringia’s Minister for Economic Affairs, Science and Digital Society.

From Pune to Mumbai

Dr Martina Schmitz faced a tight programme at four cities in only one week. From New Delhi to Pune, Coimbatore and finally Mumbai. Her itinerary started in the north and continued in the south of India, returning to the north again. Together with the other participants, our managing director visited medium-sized companies, and took part in various round tables and receptions, such as those organised by the Federation of Indian Chambers of Commerce and Industry (FICCI). Dr Martina Schmitz also visited two hospitals in Pune to have the Indian healthcare system explained to her.

Promising Contacts with Indian Companies

Representatives of Indian companies met representatives of Thuringian companies in the so-called round tables. Some of the meetings were organised in advance, but many contacts also came about spontaneously. ‘I was able to have some promising conversations’, says Dr Martina Schmitz, ‘now, back in Germany, these contacts should be checked and a follow-up should be agreed on.’

India: A Country Full of Contrasts

Dr Martina Schmitz was impressed by the different worlds that meet in India: ‘On the way to a company I drive along an alley full of people. Power cables are laid open next to the houses. There is rubbish on the street. Then I reach my destination, enter the building, and I find myself inside a glamorous office.’ Tradition and modernity also coexist closely in India. Not only during temple visits did the travellers get a Bindi, a dot pressed on their foreheads, but also during business appointments: ‘This trip provided me with a good insight of the Indian market. I am looking forward to strengthening the contacts I have established’, summarises Dr Martina Schmitz on the results of the India trip.

oncgnostics cooperates with Sayre

Bangalore/Jena, 28.04.2016 – The biotech firm oncgnostics GmbH will start distributing its molecular diagnostic test GynTect for use in cervical cancer diagnostics in an exclusive partnership with Sayre Therapeutics.

GynTect is a molecular test, which allows timely clarification, if a patient with abnormal Pap test finding and/or a positive test for the cancer-causing human papillomaviruses already has or develops a cervical disease that requires treatment. The test provides fast and reliable results and thus quick certainty for the patient. This facilitates the risk assessment for the patient drastically: unnecessarily rash decisions may be avoided, and the chances for a successful treatment are increased. GynTect is already available in the European market, it has received CE IVD mark in the end of 2015. Together with Sayre Therapeutics, oncgnostics intends to address the markets of India, Sri Lanka, Nepal, Bangladesh and Pakistan.

Dr. Alfred Hansel, CEO at oncgnostics, stated “India has the highest prevalence of cervical cancer world-wide with high mortality rates and with the country’s dedicated efforts toward cervical cancer screening , the Indian subcontinent is an attractive market for oncgnostics.”

Vandana Subramanian, Head- Business Development at Sayre stated, ” Cervical cancer, caused by Human Papillomavirus infection, is the leading cancer in Indian women, accounting to nearly 1/4th of the global cervical cancer incidences as well as deaths.

Our collaboration with oncgnostics provides a tremendous boost in our efforts to bring cutting-edge molecular diagnostic products to the Indian subcontinent. Sayre is committed to making available life-saving medicines, devices and diagnostics in South Asia, to benefit the patient community and improve their quality of life.”



Further information about GynTect® as well as the test procedure, are found here.
Find cost-free picture material concerning this press release, the test and the company here and here.


About Sayre Therapeutics:

M/S Sayre Therapeutics Private Ltd. is South Asia’s only integrated platform for disease management backed by a unique distribution and commercialization model for novel and / or differentiated drugs, companion diagnostics and drug-delivery devices in the super-specialty areas of Oncology and Immunology. Companies with novel Oncology and Immunology assets can work with us in South Asia, as we focus on alleviating life-threatening diseases with high unmet need.

For press releases and other company information, visit: or please contact for further information.